Abstract: Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.

Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.

Abstract: Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.

Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.

Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolymph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.

Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.

Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.

Abstract: A method for improving the quality of frozen seafood by enhancing flavor and shelf-life so that the seafood can be stored under commercial conditions. This method includes injection of substances into the flesh or circulatory system of live fish and whole seafood prior to cooking or freezing. These injected substances include antioxidants and cryoprotectants which circulate throughout the tissues, allowing for a uniform distribution throughout the flesh of the animal. The animal is then frozen, or cooked and then frozen, and stored for later use. The present invention is also directed to a solution for injecting into live fish and whole seafood in accordance with the method of the present invention.

Abstract: A method for preparing a vaccine suitable for use in protecting lobsters against gaffkemia, which comprises:(a) culturing a logarithmic growth phase of the bacteria Aerococcus viridans (Var. Homari) in a suitable growth medium containing sources of assimilable complete nutrients for said bacteria;(b) adding a sublethal, replication-inhibiting amount of an antibiotic effective against said bacteria to said culture and incubating the resultant admixture for a period for time sufficient to accumulate antigens therein protective against gaffkemia infections; and(c) recovering said protective antigens to form a vaccine containing an immunologically effective amount of said antigens free of said living bacteria and substantially free of in vivo effective amounts of said antibiotic.